The need for technologies to improve healing of leg ulcers in New Zealand has been recognized by the New Zealand Health Research Council (HRC) who have awarded a team led by Associate Professor Andrew Jull (University of Auckland) a Grant to conduct a fully-powered RCT comparing keramatrix® to standard care, see http://www.hrc.govt.nz/funding-opportunities/recipients/associate-professor-andrew-jull-0. Keraplast Technologies are pleased that the HRC recognise the potential for improved healing with keratin-based technology and are enthusiastically supporting this trial. Robert Allen Smith (MD), Keraplast’s medical director, says “Since developing our products, they have performed very well in-vitro as well as animal studies and many human studies and it is pleasing that HRC have recognised this potential and are funding a comprehensive clinical trial for VLUs where there is a well-recognized unmet clinical need”.